1. 361 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 12 month analysis of biomarkers and clinical outcomes. (10th December 2020) Authors: Jaderberg, Magnus; Cedres, Susana; Paz-Ares, Luis; Serres, Xavier; Ricordel, Charles; Isambert, Nicolas; Aix, Santiago Ponce; Levitsky, Victor; Kuryk, Lukasz; Moller, Anne-Sophie; Vetrhus, Sylvia Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A220 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 361 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 12 month analysis of biomarkers and clinical outcomes. (9th November 2020) Authors: Jaderberg, Magnus; Cedres, Susana; Paz-Ares, Luis; Serres, Xavier; Ricordel, Charles; Isambert, Nicolas; Aix, Santiago Ponce; Levitsky, Victor; Kuryk, Lukasz; Moller, Anne-Sophie; Vetrhus, Sylvia Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A386 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC. Issue 4 (27th April 2022) Authors: Frigola, Joan; Carbonell, Caterina; Irazno, Patricia; Pardo, Nuria; Callejo, Ana; Cedres, Susana; Martinez-Marti, Alex; Navarro, Alejandro; Soleda, Mireia; Jimenez, Jose; Hernandez-Losa, Javier; Vivancos, Ana; Felip, Enriqueta; Amat, Ramon Journal: Journal for immunotherapy of cancer Issue: Volume 10:Issue 4(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. Issue 7 (July 2019) Authors: Scagliotti, Giorgio V; Gaafar, Rabab; Nowak, Anna K; Nakano, Takashi; van Meerbeeck, Jan; Popat, Sanjay; Vogelzang, Nicholas J; Grosso, Federica; Aboelhassan, Rasha; Jakopovic, Marko; Ceresoli, Giovanni L; Taylor, Paul; Orlandi, Francisco; Fennell, Dean A; Novello, Silvia; Scherpereel, Arnaud; Ku... Journal: Lancet Issue: Volume 7:Issue 7(2019) Page Start: 569 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma. Issue 12 (December 2016) Authors: Nowak, Anna K.; Chansky, Kari; Rice, David C.; Pass, Harvey I.; Kindler, Hedy L.; Shemanski, Lynn; Billé, Andrea; Rintoul, Robert C.; Batirel, Hasan F.; Thomas, Charles F.; Friedberg, Joseph; Cedres, Susana; de Perrot, Marc; Rusch, Valerie W. Journal: Journal of thoracic oncology Issue: Volume 11:Issue 12(2016) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial. Issue 12 (December 2019) Authors: Ceresoli, Giovanni L; Aerts, Joachim G; Dziadziuszko, Rafal; Ramlau, Rodryg; Cedres, Susana; van Meerbeeck, Jan P; Mencoboni, Manlio; Planchard, David; Chella, Antonio; Crinò, Lucio; Krzakowski, Maciej; Rüssel, Jörn; Maconi, Antonio; Gianoncelli, Letizia; Grosso, Federica Journal: Lancet oncology Issue: Volume 20:Issue 12(2019) Page Start: 1702 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗